Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
133.75
-0.63 (-0.47%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 95.89M EUR in the quarter ending March 31, 2024, with 185.49% growth. This brings the company's revenue in the last twelve months to 329.02M, up 322.18% year-over-year. In the year 2023, Ascendis Pharma had annual revenue of 266.72M with 421.20% growth.
Revenue (ttm)
329.02M EUR
Revenue Growth
+322.18%
P/S Ratio
21.17
Revenue / Employee
374,315 EUR
Employees
879
Market Cap
7.57B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Ensign Group | 3.85B |
Lantheus Holdings | 1.37B |
Penumbra | 1.10B |
Halozyme Therapeutics | 862.99M |
Ionis Pharmaceuticals | 776.62M |
Repligen | 607.45M |
Blueprint Medicines | 282.21M |
Roivant Sciences | 124.80M |
ASND News
- 4 weeks ago - Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 - GlobeNewsWire
- 2 months ago - Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024 - GlobeNewsWire
- 2 months ago - FDA extends review of Ascendis Pharma's hormone disorder therapy - Reuters
- 2 months ago - Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism - GlobeNewsWire
- 2 months ago - Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial - GlobeNewsWire
- 2 months ago - Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 - GlobeNewsWire